RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Clinical trials for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA explained in plain language.
Never miss a new study
Get alerted when new RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA trials appear
Sign up with your email to follow new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy shows promise for rare 'Butterfly Skin' wounds
Disease control OngoingThis study tests a gene therapy called FCX-007 for people with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin condition causing severe blistering. The treatment uses the patient's own skin cells, modified to produce a missing protein, and is injected into wounds. …
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New eye drops aim to shed light on EB-Related eye pain
Symptom relief OngoingThis study tests whether ELK-003 eye drops can safely reduce eye symptoms in people with certain types of epidermolysis bullosa (EB), a rare skin condition that also affects the eyes. About 20 participants will first be observed without treatment, then receive the eye drops six t…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE1 • Sponsor: Fundación DEBRA Chile, Niños Piel de Cristal • Aim: Symptom relief
Last updated May 11, 2026 20:48 UTC